Targeted Oncology
Articles by Targeted Oncology
Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.
A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
Case 2: Novel Agents in Late-Stage Clinical Trials for HER2+ MBC
Published: | Updated:
Case 2: Adverse Effects of Treatments for HER2+ Breast Cancer
Published: | Updated:
Case 2: Risk Factors for Brain Metastases in HER2+ Breast Cancer
Published: | Updated:
Case 1: Subcutaneous Trastuzumab-Pertuzumab for HER2+ Breast Cancer
Published: | Updated:
Case 1: De-Escalation of Adjuvant Anti-HER2 Therapy for Breast Cancer
Published: | Updated:
Case 1: Adjuvant Therapy After pCR in Early Stage HER2+ Breast Cancer
Published: | Updated:
Case 1: Choosing Therapy for Early Stage HER2+ Breast Cancer
Published: | Updated:
Case 1: Neoadjuvant Therapy for Early-Stage HER2+ Breast Cancer
Published: | Updated:
Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.
Case 3: Management of Immune-Related Toxicities in Stage III NSCLC
Published: | Updated: